Mcmaster University

Sanofi-a Ventis Deutschland Gmbh

Gregory Steinberg

Thorsten Sadowski

Hertzel Gerstein

Sibylle Hess

Guillaume Pare

Waliul Khan

Alex Green

Palanivel Rengasamy

The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Growth differentiation factor 15 as biomarker for metformin

A method of treating obesity and obesity-related disorders in a mammal is provided. The method comprises the step of administering to the mammal a compound or entity that inhibits the HTR2a receptor.

Method of treating obesity

A method of treating obesity and obesity-related disorders in a mammal is provided. The method comprises the step of administering to the mammal a compound that inhibits the synthesis or activity of peripheral serotonin, including a Tph1 inhibitor or a serotonin receptor inhibitor.

Growing community of inventors

Ancaster, Canada

Gregory Steinberg